Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2013

View Archived Issues

Uncovering purinergic signaling as a potential drug target for autism spectrum disorders

New panels for prostate cancer diagnosis described

Johnson & Johnson reports achievements of first quarter 2013

GlaxoSmithKline presents novel PI3Kdelta inhibitors for treatment of respiratory diseases

NKTR-214 is significantly more efficacious in vivo compared to aldesleukin

CA6 is a potential novel gene biomarker for atopic dermatitis

Novel TYK2 inhibitors presented by Roche

Roche patents new CYP11B2 inhibitors

Novel tyrosine kinase inhibitors designed at Cellzome

Novel pan-pim inhibitor limits multiple myeloma tumor growth in vivo

Meiji Seika Pharma begins clinical testing of novel antifungal agent

Cipla launches biosimilar of etanercept in India

Afraxis identifies new PAK inhibitors

Novel EGFR inhibitors designed at Pfizer

Improvements in lung function observed in study of VX-661 and ivacaftor

Novel IRAK-4 inhibitors prepared at Aurigene Discovery

Pieris achieves second milestone under Anticalin collaboration

Lundbeck launches Selincro in European markets

Elan rejects Royalty Pharma's acquisition offer

Cerecor acquires rights to MK-0657 from Merck & Co.

Ceregene announces findings from phase IIb gene therapy study for Parkinson's disease

Phase II study of BI-505 in multiple myeloma begins

TiGenix reports phase IIa study results for Cx-611

BIND Therapeutics and AstraZeneca collaborate on cancer nanomedicine

FDA designates LJPC-6417 as an orphan drug product

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
First-in-class non-β-lactam targeting AMR gram-negative pathogens
BioWorld Science
Antimicrobial resistance (AMR) is increasingly compromising the effectiveness of essential antibiotics, resulting in higher global mortality and morbidity rates....